Inhalation carcinogenicity study with nickel metal powder in Wistar rats.
Epidemiological studies of nickel refinery workers have demonstrated an association between increased respiratory cancer risk and exposure to certain nickel compounds (later confirmed in animal studies). However, the lack of an association found in epidemiological analyses for nickel metal remained unconfirmed for lack of robust animal inhalation studies. In the present study, Wistar rats were exposed by whole-body inhalation to 0, 0.1, 0.4, and 1.0 mg Ni/m(3) nickel metal powder (MMAD=1.8 microm, GSD=2.4 microm) for 6 h/day, 5 days/week for up to 24 months. A subsequent six-month period without exposures preceded the final euthanasia. High mortality among rats exposed to 1.0 mg Ni/m(3) nickel metal resulted in the earlier termination of exposures in this group. The exposure level of 0.4 mg Ni/m(3) was established as the MTD for the study. Lung alterations associated with nickel metal exposure included alveolar proteinosis, alveolar histiocytosis, chronic inflammation, and bronchiolar-alveolar hyperplasia. No increased incidence of neoplasm of the respiratory tract was observed. Adrenal gland pheochromocytomas (benign and malignant) in males and combined cortical adenomas/carcinomas in females were induced in a dose-dependent manner by the nickel metal exposure. The incidence of pheochromocytomas was statistically increased in the 0.4 mg Ni/m(3) male group. Pheochromocytomas appear to be secondary to the lung toxicity associated with the exposure rather than being related to a direct nickel effect on the adrenal glands. The incidence of cortical tumors among 0.4 mg Ni/m(3) females, although statistically higher compared to the concurrent controls, falls within the historical control range; therefore, in the present study, this tumor is of uncertain relationship to nickel metal exposure. The lack of respiratory tumors in the present animal study is consistent with the findings of the epidemiological studies.
Oller
Adriana R
AR
NiPERA, 2605 Meridian Parkway, Suite 200, Durham, NC 27713, USA. aoller@nipera.org
Kirkpatrick
Daniel T
DT
Radovsky
Ann
A
Bates
Hudson K
HK
D000306:Adrenal Cortex Neoplasms / Q000139:chemically induced; D000310:Adrenal Gland Neoplasms / Q000139:chemically induced; D018246:Adrenocortical Adenoma / Q000139:chemically induced; D018268:Adrenocortical Carcinoma / Q000139:chemically induced; D000818:Animals; D015197:Carcinogenicity Tests / Q000379:methods*; D002273:Carcinogens / Q000008:administration & dosage / Q000633:toxicity*; D004305:Dose-Response Relationship, Drug; D005260:Female; D019570:Inhalation Exposure / Q000009:adverse effects*; D008168:Lung / Q000187:drug effects* / Q000473:pathology; D008297:Male; D023421:Models, Animal; D009532:Nickel / Q000008:administration & dosage / Q000633:toxicity*; D016273:Occupational Exposure / Q000009:adverse effects; D010673:Pheochromocytoma / Q000139:chemically induced; D011208:Powders; D051381:Rats; D017208:Rats, Wistar; D012142:Respiratory Tract Neoplasms / Q000453:epidemiology / Q000209:etiology; D012737:Sex Factors
D002273:Carcinogens; D011208:Powders; D009532:Nickel